Skip to main content
SpringerLink
Log in

Symptom Management

  • Chapter
  • First Online:
Handbook of Multiple Sclerosis

  • 1852 Accesses

Abstract

Multiple sclerosis (MS) potentially produces a wide variety of symptoms, either during acute relapses or chronically. The combination of symptoms and their severity vary markedly from patient to patient and in individual patients over time. MS symptoms can interfere with daily activities or lessen quality of life (QOL), and many are amenable to treatment. Thus identification and treatment of symptoms is an important aspect of MS management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Goldman MD, Cohen JA, Fox RJ, et al. Multiple sclerosis: treating symptoms and other general medical issues. Cleve Clin J Med. 2006;73:177-186.

    Google Scholar 

  2. Boissy AR, Cohen JA. Multiple sclerosis symptom treatment. Expert Rev Neurother. 2007;7:1213-1222.

    Google Scholar 

  3. Hemmett L, Holmes J, Barnes M, et al. What drives quality of life in multiple sclerosis? Q J Med. 2004;97:671-676.

    Google Scholar 

  4. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112:133-146.

    Google Scholar 

  5. Myhr KM, Riise T, Vedeler C, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler. 2001;7:59-65.

    Google Scholar 

  6. Paltamaa J, Sarasoja T, Leskinen E, et al. Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehabil.2007;88:1649-1657.

    Google Scholar 

  7. Wu N, Minden SL, Hoaglin DC, et al. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm. 2007;30:233-267.

    Google Scholar 

  8. Salter AR, Cutter GR, Tyry T, et al. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin. 2010;26:493-500.

    Google Scholar 

  9. Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11:232-239.

    Google Scholar 

  10. Moreau R, Salter AR, Tyry T, et al. Work absenteeism and mobility levels in the NARCOMS registry. Poster S95 presented at the 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers, June 2-5, 2010, San Antonio, Texas.

    Google Scholar 

  11. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373:732-738.

    Google Scholar 

  12. Goodman AD, Brown TR, Edwards KR, et al. A Phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68:494-502.

    Google Scholar 

  13. Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: what is a reliable change? Neurology. 2002;58:1294-1296.

    Google Scholar 

  14. Ampyra (dalfampridine) extended release tablets. Risk evaluation and mitigation strategy. www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000REMS.pdf. Accessed March 9, 2012.

  15. Frohman EM, Zhang H, Dewey RB, et al. Vertigo in MS: utility of positional and particle repositioning maneuvers. Neurology. 2000;55:1566-1568.

    Google Scholar 

  16. Poser S, Wikstrom J, Bauer HJ. Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J Neurol Sci. 1979;40:159-168.

    Google Scholar 

  17. Goodin DS. Survey of multiple sclerosis in northern California. Mult Scler. 1999;5:77-88.

    Google Scholar 

  18. Haselkorn JK, Balsdon Richer C, Fry-Welch D, et al. Multiple Sclerosis Council for Clinical Practice Guidelines: spasticity management in multiple sclerosis. J Spinal Cord Med. 2005;28:167-199.

    Google Scholar 

  19. Yablon SA, Brin MF, VanDenburgh AM, et al. Dose response with onabotulinumtoxinA for poststroke spasticity: a pooled data analysis. Mov Disord. 2011;26:209-215.

    Google Scholar 

  20. Montgomery EB, Baker KB, Kinkel RP, et al. Chronic thalamic stimulation for the tremor of multiple sclerosis. Neurology. 1999;53:625-628.

    Google Scholar 

  21. Seland TP, Brunette J, Clesson IM, et al. Clinical Practice Guidelines: Urinary Dysfunction and Multiple Sclerosis. Multiple Sclerosis Council for Clinical Practice Guidelines, 1999. Consortium for MS Centers. mscare.org/cmsc/index.php. Accessed March 9, 2012.

    Google Scholar 

  22. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742-750.

    Google Scholar 

  23. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and safety study of onabotulinumtoxina in patients with urinary incontinence due to neurogenic detrusor overactivity. Abstract presented at the American Urological Association annual meeting 2011; abstract 1515.

    Google Scholar 

  24. Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41:685-691.

    Google Scholar 

  25. Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41:692-696.

    Google Scholar 

  26. Villoslada P, Arrondo G, Sepulcre J, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology. 2009;72:1630-1633.

    Google Scholar 

  27. Sadovnick A, Eisen K, Ebers GC, et al. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991;41:1193-1196.

    Google Scholar 

  28. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology. 1996;46:628-632.

    Google Scholar 

  29. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002;59:674-678.

    Google Scholar 

  30. Edwards L, Constantinescu C. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis center. Mult Scler. 2004;10:575-581.

    Google Scholar 

  31. Wada K, Yamada N, Sato T, et al. Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. Psychosomatics. 2001;42:461-466.

    Google Scholar 

  32. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology. 1993;43:655-661.

    Google Scholar 

  33. Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59:780-787.

    Google Scholar 

  34. Pioro EP, Brooks BR, Cumming J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68:693-702.

    Google Scholar 

  35. Kinkel RP, Conway K, Copperman L, et al. Clinical Practice Guidelines: Fatigue and Multiple Sclerosis. Multiple Sclerosis Council for Clinical Practice Guidelines, 1998. Consortium of MS Centers. mscare.org/cmsc/index.php. Accessed March 9, 2012.

    Google Scholar 

  36. Wingerchuk DM, Benarroch EE, O’Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology. 2005;64:1267-1269.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic, Cleveland, OH, USA

    Jeffrey A. Cohen

  2. Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA

    Alexander Rae-Grant

Authors
  1. Jeffrey A. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Rae-Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springher Healthcare

About this chapter

Cite this chapter

Cohen, J.A., Rae-Grant, A. (2012). Symptom Management. In: Handbook of Multiple Sclerosis. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-50-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-50-4_6

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-49-4

  • Online ISBN: 978-1-907673-50-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation